Adheris, the largest provider of direct-to-patient medication adherence programs, has chosen Cleveland-based CellepathicRx as its mobile platform provider. The partnership expands Adheris' delivery of its adherence-focused programs beyond mail to all mobile technology platforms -- text, email, web, and more.

"Medical adherence is a $300 billion a year problem," says Greg Muffler, CEO of CellepathicRx. "Our technology is a mobile platform that creates an ongoing intimate relationship with patients and their providers."

CellepathicRx's mobile health communication platform targets patients to help them understand and adhere to medication regimens, clinical trial protocols, health coaching, and health and wellness programs. The technology has been in development for more than two years, and was released in 2009.

"We chose CellepathicRx because of their deep knowledge of healthcare, retail pharmacies, and pharmaceutical industry technology, as well as the unique, flexible solution they offer," said Jim Rotsart, executive vice president of Adheris. "The use of mobile applications and texting is skyrocketing, so this relationship gives our pharmacy partners the opportunity to offer their patients choices regarding their healthcare -- whether it be receiving reminders, medication education, and/or copay assistance via email, mobile device, or traditional mail."

Muffler calls the relationship with Adheris a milestone for the company. "It's an inexpensive way to develop an ongoing relationship with patients," he says. "Our main goal is to ultimately improve patient outcomes, improve health and wellness, which we believe will have an impact on healthcare costs by getting people to take control of their own healthcare."


Source: Greg Muffler
Writer: Karin Connelly